From the looks of things, not much. Is the Facet Gun innovation? I'm not quite sure, since most surgeons that I have spoken to are not enamored with this product. Could this be the beginning of another Vertebron scenario? Remember, Sendro grew Vertebron threefold, as reported in the U.S. Spine press release, only to result in Chapter 7 and Chapter 11 bankruptcy. In addition, how many medical advisors can a company of this size have? The Spine Blogger would be surprised if this company generates $12 million in sales per annum. If so, that would be $1 million per medical advisor. The Spine Blogger wants to know what you foot soldiers have heard, could this be the beginning of the end for another spine company?